Related Experiment Video
Updated: Nov 15, 2025
08:52
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
Published on: June 13, 2018
9.1K
Survivorship and prognostic factors for pleomorphic liposarcoma: a population-based study
Lu Wan1,2,3, Chao Tu1,3, Lin Qi1,3
1Department of Orthopedics, The Second Xiangya Hospital, Central South University, 139 Renming Road, Changsha, 410011, Hunan, People's Republic of China.
Journal of Orthopaedic Surgery and Research
|March 5, 2021
Summary
Pleomorphic liposarcoma survival rates remain unchanged. Surgery improves outcomes, while radiotherapy benefits only large tumors; distant stage indicates poor prognosis. Surveillance should extend to 10 years.
Area of Science:
- Oncology
- Surgical Oncology
- Cancer Research
Background:
- Pleomorphic liposarcoma is a rare and aggressive cancer.
- Limited data exists on its long-term survival and prognostic factors.
- Understanding these characteristics is crucial for patient management.
Purpose of the Study:
- To analyze the survivorship and prognostic factors of pleomorphic liposarcoma.
- To identify key variables influencing patient survival.
- To inform clinical surveillance and treatment strategies.
Main Methods:
- Utilized a cross-sectional analysis of the Surveillance Epidemiology and End Results (SEER) database.
- Examined data from 1996 to 2015.
- Employed univariate, multivariate, and competing risk analyses.
Main Results:
- Overall survival at 5 and 10 years was 54% and 40%, respectively.
- Disease-specific survival at 5 and 10 years was 60% and 53%, respectively.
- Cancer-directed surgery was a significant positive prognostic factor; radiotherapy benefited tumors >10 cm; distant stage predicted poor outcomes.
Conclusions:
- Pleomorphic liposarcoma survival rates have not improved in 20 years.
- Surgery is vital; radiotherapy is beneficial for large tumors (>10 cm).
- Extended surveillance (≥10 years) is recommended for patients.
